Bazelet Medical Cannabis Group, Or Akiva, Israel.
Department of Anesthesiology, CCM and Pain Relief, Hadassah Hebrew University Hospital Jerusalem, Israel.
Biochem Pharmacol. 2023 Jun;212:115548. doi: 10.1016/j.bcp.2023.115548. Epub 2023 Apr 19.
The cannabis plant exerts its pharmaceutical activity primarily by the binding of cannabinoids to two G protein-coupled cannabinoid receptors, CB1 and CB2. The role that cannabis terpenes play in this activation has been considered and debated repeatedly, based on only limited experimental results. In the current study we used a controlled in-vitro heterologous expression system to quantify the activation of CB1 receptors by sixteen cannabis terpenes individually, by tetrahydrocannabinol (THC) alone and by THC-terpenes mixtures. The results demonstrate that all terpenes, when tested individually, activate CB1 receptors, at about 10-50% of the activation by THC alone. The combination of some of these terpenes with THC significantly increases the activity of the CB1 receptor, compared to THC alone. In some cases, several fold. Importantly, this amplification is evident at terpene to THC ratios similar to those in the cannabis plant, which reflect very low terpene concentrations. For some terpenes, the activation obtained by THC- terpene mixtures is notably greater than the sum of the activations by the individual components, suggesting a synergistic effect. Our results strongly support a modulatory effect of some of the terpenes on the interaction between THC and the CB1 receptor. As the most effective terpenes are not necessarily the most abundant ones in the cannabis plant, reaching "whole plant" or "full spectrum" composition is not necessarily an advantage. For enhanced therapeutic effects, desired compositions are attainable by enriching extracts with selected terpenes. These compositions adjust the treatment for various desired medicinal and personal needs.
大麻植物主要通过大麻素与两种 G 蛋白偶联大麻素受体 CB1 和 CB2 的结合来发挥其药用活性。大麻萜烯在这种激活中的作用已经被反复考虑和争论过,这仅仅基于有限的实验结果。在目前的研究中,我们使用了一种受控的体外异源表达系统,单独测试了十六种大麻萜烯、四氢大麻酚(THC)单独以及 THC-萜烯混合物对 CB1 受体的激活作用。结果表明,所有萜烯在单独测试时都会激活 CB1 受体,其激活程度约为 THC 单独激活的 10-50%。当与 THC 结合使用时,这些萜烯中的一些组合会显著增加 CB1 受体的活性,与 THC 单独使用相比,在某些情况下增加了几倍。重要的是,这种放大作用在萜烯与 THC 的比例与大麻植物中的相似,反映了萜烯的浓度非常低。对于一些萜烯,THC-萜烯混合物的激活作用明显大于单个成分的激活作用之和,表明存在协同作用。我们的研究结果强烈支持了一些萜烯对 THC 与 CB1 受体相互作用的调节作用。由于最有效的萜烯不一定是大麻植物中含量最丰富的萜烯,因此达到“全植物”或“全谱”组成不一定是优势。为了增强治疗效果,可以通过用选定的萜烯富集提取物来获得所需的组合物。这些组合物可根据各种所需的医疗和个人需求来调整治疗方案。